Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants

Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the preva...

Full description

Saved in:
Bibliographic Details
Published inEJHaem Vol. 5; no. 5; pp. 1021 - 1027
Main Authors Mestre, Julia, Chaparro, Lorea, Manzanares, Ana, Xicoy, Blanca, Zamora, Lurdes, Sole, Francesc, Calvete, Oriol
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.10.2024
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text
ISSN2688-6146
2688-6146
DOI10.1002/jha2.1012

Cover

Abstract Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
AbstractList Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
Abstract Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3 cells. All the selected variants were not found in CD3 cells except one variant in the gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold.IntroductionGermline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold.A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells.MethodsA total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells.All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%.ResultsAll the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%.Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.ConclusionOur study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
Author Mestre, Julia
Manzanares, Ana
Xicoy, Blanca
Chaparro, Lorea
Sole, Francesc
Zamora, Lurdes
Calvete, Oriol
AuthorAffiliation 3 Department of Hematology ICO‐IJC‐Hospital Germans Trias i Pujol, UAB Badalona Catalonia Spain
2 Facultat de Biociències Universitat Autònoma de Barcelona Barcelona Spain
1 MDS Group Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona Badalona Spain
AuthorAffiliation_xml – name: 2 Facultat de Biociències Universitat Autònoma de Barcelona Barcelona Spain
– name: 1 MDS Group Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona Badalona Spain
– name: 3 Department of Hematology ICO‐IJC‐Hospital Germans Trias i Pujol, UAB Badalona Catalonia Spain
Author_xml – sequence: 1
  givenname: Julia
  orcidid: 0000-0002-4809-3897
  surname: Mestre
  fullname: Mestre, Julia
  organization: Universitat Autònoma de Barcelona
– sequence: 2
  givenname: Lorea
  orcidid: 0009-0008-6806-9342
  surname: Chaparro
  fullname: Chaparro, Lorea
  organization: Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona
– sequence: 3
  givenname: Ana
  surname: Manzanares
  fullname: Manzanares, Ana
  organization: Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona
– sequence: 4
  givenname: Blanca
  orcidid: 0000-0002-0295-1307
  surname: Xicoy
  fullname: Xicoy, Blanca
  organization: ICO‐IJC‐Hospital Germans Trias i Pujol, UAB
– sequence: 5
  givenname: Lurdes
  orcidid: 0000-0003-1713-7110
  surname: Zamora
  fullname: Zamora, Lurdes
  organization: ICO‐IJC‐Hospital Germans Trias i Pujol, UAB
– sequence: 6
  givenname: Francesc
  orcidid: 0000-0002-3251-2161
  surname: Sole
  fullname: Sole, Francesc
  email: fsole@carrerasresearch.org
  organization: Universitat Autònoma de Barcelona
– sequence: 7
  givenname: Oriol
  orcidid: 0000-0002-2623-2876
  surname: Calvete
  fullname: Calvete, Oriol
  email: ocalvete@carrerasresearch.org
  organization: Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39415912$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAQgC1UREvpgRdAkbjAYWn8mzWXqlRAiypxqbhaXnuy8cqxg50U7QPw3ji7ZdUicbA88nz-NPbMS3QUYgCEXuP6A65rcr7pNCkRJs_QCRHL5UJgJo4excfoLOdNXViKuaD4BTqmkmEuMTlBvz_BNgZb9Vvw0dkqQBy8zn2u1pB67wJU68lZmKP8sfqhvbN6dDFUsa3GDspKkLvoba5MciMkpysXdqkMOpluBg-uIYF1eYjZ7Rz3uuBhzK_Q81b7DGcP-ym6-_L57up6cfv9683V5e3CMNGQBRBJZdtyboQ02nDCCOOU1owBA2pMebFmFngjCG81WCLACmBkxWzLMKOn6GavtVFv1JBcr9NWRe3U7iCmtdJpdMaDatpa2KUGDZwysWIaCyaZoITaVjaNLa6LvWuYVj1YA2FM2j-RPs0E16l1vFcYs4ZRKYvh3YMhxZ8T5FH1LhvwXpcmTFlRjBuBJeG8oG__QTdxSqF81UwJTpqaN4V687ikQy1_u12A93vApJhzgvaA4FrNw6TmYVLzMBX2fM_-ch62_wfVt-tLsrvxBywmzGs
Cites_doi 10.1038/s41375-022-01729-4
10.1007/s00428‐022‐03447‐9
10.18632/oncotarget.23882
10.1111/bjh.18675
10.3390/ijms17060838
10.1097/HS9.0000000000000321
10.1182/blood.2022015790
10.1182/bloodadvances.2019001127
10.1182/blood.2022015853
10.1111/bjh.18676
10.6004/jnccn.2022.0009
10.1038/s41576-019-0139-x
ContentType Journal Article
Copyright 2024 The Author(s). published by British Society for Haematology and John Wiley & Sons Ltd.
2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Author(s). published by British Society for Haematology and John Wiley & Sons Ltd.
– notice: 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/jha2.1012
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection
ProQuest Biological Science Collection
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ) (Open Access)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate MESTRE et al
EISSN 2688-6146
EndPage 1027
ExternalDocumentID oai_doaj_org_article_7f06d8aeae5346b4a164946323df977d
PMC11474399
39415912
10_1002_jha2_1012
JHA21012
Genre shortCommunication
Journal Article
GrantInformation_xml – fundername: Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
  funderid: 2023 FI‐1 00200
– fundername: Instituto de Salud Carlos III
  funderid: PI 20/000531; PI23/00007
– fundername: Joan Oró predoctoral programfrom Secretariad' Universitat siRecercadel Departamentde Recercai Universitats delaGeneralitatde Catalunya
– fundername: European Social Funding Plus (FSE+)
– fundername: José Carreras Leukämie‐Stiftung 2020
  funderid: DJCLS01R/2021; 2021SGR00560
– fundername: (GRC) Generalitat de Catalunya: CERCA Programme/Generalitat de Catalunya
– fundername: Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
  grantid: 2023 FI‐1 00200
– fundername: José Carreras Leukämie‐Stiftung 2020
  grantid: DJCLS01R/2021; 2021SGR00560
GroupedDBID 0R~
1OC
24P
53G
AAHHS
ACCFJ
ACCMX
ACXQS
ADKYN
ADPDF
ADZMN
AEEZP
AEQDE
AFKRA
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BBNVY
BENPR
BHPHI
CCPQU
EBS
GROUPED_DOAJ
HCIFZ
IAO
IHR
INH
ITC
M7P
M~E
OVD
OVEED
PGMZT
PIMPY
RPM
TEORI
WIN
AAFWJ
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
NPM
8FE
8FH
AAMMB
ABUWG
AEFGJ
AGXDD
AIDQK
AIDYY
AZQEC
DWQXO
GNUQQ
LK8
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c4672-e2939ff55c69cac52424533044e4e3cc688a4de57625faed26ed6e42b4df4143
IEDL.DBID 24P
ISSN 2688-6146
IngestDate Wed Aug 27 01:27:37 EDT 2025
Thu Aug 21 18:31:24 EDT 2025
Fri Sep 05 09:46:05 EDT 2025
Wed Aug 13 10:35:25 EDT 2025
Wed Feb 19 02:01:37 EST 2025
Tue Jul 01 04:19:30 EDT 2025
Wed Jan 22 17:13:33 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords myelodysplastic syndromes (MDS)
variant allele frequency (VAF)
germline guidelines
germline predisposition
Language English
License Attribution-NonCommercial-NoDerivs
2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4672-e2939ff55c69cac52424533044e4e3cc688a4de57625faed26ed6e42b4df4143
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-3251-2161
0000-0002-4809-3897
0000-0003-1713-7110
0000-0002-2623-2876
0009-0008-6806-9342
0000-0002-0295-1307
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.1012
PMID 39415912
PQID 3116527057
PQPubID 5066168
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_7f06d8aeae5346b4a164946323df977d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11474399
proquest_miscellaneous_3117619255
proquest_journals_3116527057
pubmed_primary_39415912
crossref_primary_10_1002_jha2_1012
wiley_primary_10_1002_jha2_1012_JHA21012
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2024
PublicationDateYYYYMMDD 2024-10-01
PublicationDate_xml – month: 10
  year: 2024
  text: October 2024
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle EJHaem
PublicationTitleAlternate EJHaem
PublicationYear 2024
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2022; 36
2018; 9
2022; 140
2020; 4
2019; 20
2016; 17
2023; 482
2022 Feb; 20
2022
2019 Dec; 3
2023; 201
e_1_2_13_13_1
e_1_2_13_14_1
e_1_2_13_15_1
e_1_2_13_10_1
e_1_2_13_11_1
e_1_2_13_12_1
e_1_2_13_9_1
e_1_2_13_8_1
e_1_2_13_7_1
e_1_2_13_6_1
e_1_2_13_5_1
e_1_2_13_4_1
e_1_2_13_3_1
e_1_2_13_2_1
References_xml – volume: 9
  start-page: 9714
  issue: 11
  year: 2018
  end-page: 9727
  article-title: Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
  publication-title: Oncotarget
– volume: 3
  issue: 6
  year: 2019 Dec
  article-title: Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management, and follow‐up
  publication-title: . Hemasphere.
– volume: 20
  start-page: 106
  issue: 2
  year: 2022 Feb
  end-page: 117
  article-title: NCCN Guidelines® Insights: myelodysplastic syndromes, Version 3.2022
  publication-title: J Natl Compr Canc Netw
– volume: 201
  issue: 1
  year: 2023
  article-title: Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?
  publication-title: Br J Haematol
– year: 2022
– volume: 140
  start-page: 2533
  issue: 24
  year: 2022
  end-page: 2548
  article-title: Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages
  publication-title: Blood
– volume: 36
  start-page: 2827
  issue: 12
  year: 2022
  end-page: 2834
  article-title: Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia
  publication-title: Leukemia
– volume: 4
  start-page: 1192
  issue: 7
  year: 2020
  end-page: 1196
  article-title: The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing
  publication-title: Blood Adv
– volume: 17
  start-page: 838
  issue: 6
  year: 2016
  article-title: hereditary predispositions to myelodysplastic syndrome
  publication-title: Int J Mol Sci
– volume: 140
  start-page: 2228
  issue: 21
  year: 2022
  end-page: 2247
  article-title: Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
  publication-title: Blood
– volume: 20
  start-page: 582
  issue: 10
  year: 2019
  end-page: 598
  article-title: Somatic genetic rescue in Mendelian haematopoietic diseases
  publication-title: Nat Rev Genet
– volume: 482
  start-page: 113
  issue: 1
  year: 2023
  end-page: 130
  article-title: The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia
  publication-title: Virchows Archiv [Internet]
– volume: 201
  start-page: 25
  issue: 1
  year: 2023
  end-page: 34
  article-title: Germline predisposition to haematological malignancies: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene‐CanVar and the NHS England Haematological Oncology Working Group
  publication-title: Br J Haematol
– ident: e_1_2_13_10_1
  doi: 10.1038/s41375-022-01729-4
– ident: e_1_2_13_4_1
  doi: 10.1007/s00428‐022‐03447‐9
– ident: e_1_2_13_15_1
  doi: 10.18632/oncotarget.23882
– ident: e_1_2_13_8_1
  doi: 10.1111/bjh.18675
– ident: e_1_2_13_2_1
  doi: 10.3390/ijms17060838
– ident: e_1_2_13_6_1
  doi: 10.1097/HS9.0000000000000321
– ident: e_1_2_13_7_1
– ident: e_1_2_13_9_1
  doi: 10.1182/blood.2022015790
– ident: e_1_2_13_12_1
  doi: 10.1182/bloodadvances.2019001127
– ident: e_1_2_13_14_1
  doi: 10.1182/blood.2022015853
– ident: e_1_2_13_11_1
  doi: 10.1111/bjh.18676
– ident: e_1_2_13_3_1
– ident: e_1_2_13_5_1
  doi: 10.6004/jnccn.2022.0009
– ident: e_1_2_13_13_1
  doi: 10.1038/s41576-019-0139-x
SSID ssj0002315631
Score 2.2734017
Snippet Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele...
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency...
Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele...
Abstract Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1021
SubjectTerms CD3 antigen
Clinical practice guidelines
DNA methylation
Gene frequency
germline guidelines
germline predisposition
Lymphocytes
myelodysplastic syndromes (MDS)
Patients
Point mutation
Short Report
Trends
Tumors
variant allele frequency (VAF)
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NTxsxEB1VHKpeqtLPbSkyqIdeVgR_7bo3iooiJDjRitvKa8_SoLJBhCDxA_jfnbE3UaK26oVDpCh2IsczY79Zv3kG-IQuhFhbU0Y78qVuUZVt5RxFvI3WOhNtquI_ObXj7_r43JyvXPXFnLAsD5wnbq_q6Fu1R49GadtqT_jeaaukih1hl8ir78iNVpKpyyTiQnmJ2l9ICY3k3iUXrrKY1doGlHT6_wYu_-RIrmLXtPkcvYDnA2oUB3m0m_AE-5fw9GQ4F38FD7kQRVzd46_pJIqeeeF-djUTF7TyMpIUF3MWtGKS-xfxg8B3vktJTDtBEJBelHbzSdRM0DLC-s1eTPrUlGOBOy5_6_qGq3kXfC9xR_k202lew9nRt7PDcTlcsFAGWh9libTXu64zJlgXfDBcKsJsU61RowrB1rXXESklkabzGKXFaFHLVsdOE9B6Axv9tMd3IBin0Xx30RvUVXB1rKhvbVXlsQ77bQG7i0lvrrOMRpMFk2XDlmGmmSzgK5tj2YGVr9MH5A_N4A_N__yhgK2FMZshHGeNYpEhWRE2LWBn2UyBxKcjnmwyT334kQ6lWAW8zbZfjkQ5wjmOR1ivecXaUNdb-snPJNZN-WbK-Qr4nBzo33-_OR4fSH7z_jHm4QM8k4S_Mu9wCzZub-b4kfDTbbudQuU3W9IapQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7SDZReQvp2kxa19NCLSaKXrUIpSUlYAllKSUtuRpbk7YbE3uxmC_0B_d-dkR_t0sfBYCxhJI9m_I008w3A62Cc87lWqdf7NpVlEGmZGYMar73WRnkds_jPJnr8WZ5eqIsNmPS5MBRW2dvEaKh942iPfE8QTwzPEF68n9-kVDWKTlf7Ehq2K63g30WKsTuwyamq8gg2j44nHz8Nuy6IZpQWBz3F0D7fu6SEViK5WvsxRf7-v4HOP2Mnf8e08ad0sg1bHZpkh63478NGqB_A3bPuvPwh_GgTVNj193DVzDyrKV7cLq-XbIoWmRAmm66I6IqC39-yLwjK2xpLrKkYQkO80B2nE6olQ_NCvM6WzerY1OoIdRzeNV9Qlm8fB8a-oR9OYTaP4Pzk-PzDOO0KL6QO7SZPA2IAU1VKOW2cdYpSSCgKVcogg3BO57mVPqCrwlVlg-c6eB0kL6WvJAKwxzCqmzo8BUb4Db935a0KMnMm9xn2zbXIbMjdQZnAq_6jF_OWXqNoiZR5QZKhCDSewBGJY-hAjNjxQbOYFp2CFVmFqyu3wQYlpC6lRT_QSC248BViXJ_Abi_MolPTZfFrUSXwcmhGBaNTE4syWcU-tNWDrlcCT1rZDyMRBvGPoRHma6tibajrLfXsayTxRj80-oIJvIkL6N_TL07Hh5xunv1_CjtwjyPiaiMNd2F0u1iF54iYbssXnRr8BI7tGN4
  priority: 102
  providerName: ProQuest
Title Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.1012
https://www.ncbi.nlm.nih.gov/pubmed/39415912
https://www.proquest.com/docview/3116527057
https://www.proquest.com/docview/3117619255
https://pubmed.ncbi.nlm.nih.gov/PMC11474399
https://doaj.org/article/7f06d8aeae5346b4a164946323df977d
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fSxwxEB6sQumL9HfX2iMtPvRlUbNJdqNPWpRDUES0-LZkk-z1St2TW0_wD-j_3Zlkd-vRFvpwsFzmjmwmk3wzmfkCsOW1ta5QMnVqx6Si8lla5VqjxSunlJZOhSr-0zM1vhIn1_J6Bfb7WpjIDzEE3MgywnpNBm6qdvs3aeh3qkQldqonsLZLuz7ROovzIcCCwEWqcB8hVzgbcBtSPbPQDt8efr20HwXa_r9hzT9TJh9D2bAXHT-H9Q5EsoOo9Rew4puX8PS0OyZ_BT9jXQq7efA_ZlPHGkoTN-1Nyya4ENOrs8mC-K0o532PfUUsHq9WYrOaISLED3rhdDDVMlxViM7ZsGkTmqJpkODwX7dzKu7t07_YPbrflF3zGi6Pjy6_jNPuvoXU4nLJU49bv65rKa3S1lhJlSOUfCqEFz6zFofRCOfRQ-GyNt5x5Z3yglfC1QI18AZWm1nj3wEj2IZjXzsjvcitLlyOsoXKcuMLu1sl8Kkf9PI2smqUkT-Zl6QZSjzjCRySOgYBIsIOX8zmk7KzqzKvcVIVxhsvM6EqYdD900JlPHM1QluXwGavzLKzzrbMiHOI5whVE_g4NKNd0WGJQZ0sggxFeNDjSuBt1P3Qk0wj7NHUw2JpVix1dbmlmX4L3N04U4MLmMDnMIH-_frlyfiA08PG_4u-h2ccQVdMNtyE1bv5wn9A0HRXjYJxjGDt8Ojs_GIUQg-jENv6BQvDF5g
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwEB2VVgJeEHcCBQwCiZeorWM7CVKFWmi1vewKoQX1LXJsZ1lEk2XTBfUD-Cz-jRnnAisub31YKVpbkeOZsc_YM2cAnrnUGJsoGVq1qUORuyjM4zRFi1dWqVRa5bP4hyM1eC8OT-TJCvzocmEorLJbE_1CbStDZ-QbEfHE8BjhxavZl5CqRtHtaldCQ7elFey2pxhrEzuO3Pk3dOHq7YM3KO_nnO_vjV8PwrbKQGhwkeChww0vLQopjUqNNpLyJSjkUggnXGSMShItrENczmWhneXKWeUEz4UtBKINfO0lWEPUEaFRre3ujd6-6w95EDxJFW11jEabfOMT5c8Sp9bSPujLBfwN4_4Zqvk7hPZ74P51uNaCV7bTaNsNWHHlTbg8bK_nb8H3Jh-GnZ67z9XUspLC03V9WrMJbgAEaNlkQbxaFGv_kn1AH6Ap6cSqgiESxR96_3QhVjNczYhGWrNp6ZuauaaO_btmc0oq7sLO2Fd0-ymq5zaML0ICd2C1rEp3DxjBRZzvwmrpRGzSxMbYN1FRrF1itvIAnnaTns0aNo-s4W3mGUmGAt54ALskjr4DEXD7P6r5JGvtOYsLVOZEO-1kJFQuNLqdqVARj2yBkNoGsN4JM2tXhTr7pcMBPOmb0Z7pkkajTBa-D50soacXwN1G9v1IohThVkojTJa0Ymmoyy3l9KPnDEe317ueAbzwCvTvz88OBzucHu7__xMew5XBeHicHR-Mjh7AVY5grwlyXIfVs_nCPUSwdpY_ak2CQXbBRvgTI6xUww
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4amzTxgrgvMMAgkHiJujmOEyNNaGOruo1VExpob5FjO6WIJaVpQfsB_Dj-Fec4SaHi8raHSlF9FDk-F3_HPheA504ZY1MZh1Zu6VDkLgrzRCnUeGmlVLGVPov_ZCgH78XReXy-Aj-6XBgKq-xsojfUtjJ0Rt6LqE4MTxBe9Io2LOJ0v_968iWkDlJ009q109BtmwW748uNtUkex-7yG7pz9c7hPvL-Bef9g7M3g7DtOBAaNBg8dLj5qaKIYyOV0Sam3AkKvxTCCRcZI9NUC-sQo_O40M5y6ax0gufCFgKRB772GqwluOmjsq3tHQxP3y0OfBBIxTLa7qobbfHeJ8qlpfpaS3uibx3wN7z7Z9jm73Da74f9m3CjBbJst5G8W7DiytuwftJe1d-B701uDLu4dJ-rsWUlharr-qJmI9wMCNyy0ZxqbFHc_Sv2Af2Bpr0TqwqGqBR_U1fT5VjN0LJRSWnNxqUfataaCBfvmkwpwbgLQWNfNZKXs_ounF0FB-7BalmVbgMYQUdc78Lq2InEqNQmSJvKKNEuNdt5AM-6Rc8mTWWPrKnhzDPiDAW_8QD2iB0LAirG7f-opqOs1e0sKVCwU-20iyMhc6HRBVVCRjyyBcJrG8Bmx8ystRB19kueA3i6GEbdpgsbjTyZexo6ZUKvL4D7De8XM4kUQi9FM0yXpGJpqssj5fijrx-OLrB3QwN46QXo35-fHQ12OT08-P8nPIF1VMbs7eHw-CFc54j7mnjHTVidTefuEeK2Wf641QgG2RXr4E_pDlj-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beyond+myeloid+neoplasms+germline+guidelines%3A+Validation+of+the+thresholds+criteria+in+the+search+of+germline+predisposition+variants&rft.jtitle=EJHaem&rft.au=Mestre%2C+Julia&rft.au=Chaparro%2C+Lorea&rft.au=Manzanares%2C+Ana&rft.au=Xicoy%2C+Blanca&rft.date=2024-10-01&rft.issn=2688-6146&rft.eissn=2688-6146&rft.volume=5&rft.issue=5&rft.spage=1021&rft.epage=1027&rft_id=info:doi/10.1002%2Fjha2.1012&rft.externalDBID=10.1002%252Fjha2.1012&rft.externalDocID=JHA21012
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2688-6146&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2688-6146&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2688-6146&client=summon